

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/03/31	2016/12/31	2016/03/31
<b>Balance Sheet</b>			
<b>Current assets</b>			
Total cash and cash equivalents	210,339	309,771	458,006
Total Current investments in debt instrument without active market	448,871	455,399	610,826
Accounts receivable, net	17,536	23,328	5,575
Accounts receivable due from related parties, net	289	24,472	30
Other receivables, net	5,313	2,838	12,380
Total current tax assets	1,973	1,907	4,212
Total inventories	54,686	50,395	24,433
Total prepayments	22,185	19,989	33,833
Total other current assets	48,586	48,402	10,031
<b>Total current assets</b>	<b>809,778</b>	<b>936,501</b>	<b>1,159,326</b>
<b>Non-current assets</b>			
Non-current financial assets at cost, net	20,000	20,000	0
Total Non-current investments in debt instrument without active market	0	30,000	30,000
Total property, plant and equipment	351,545	315,000	216,570
Total intangible assets	2,108	2,342	368
Deferred tax assets	39,027	39,599	39,672
Total other non-current assets	86,400	45,906	16,019
<b>Total non-current assets</b>	<b>499,080</b>	<b>452,847</b>	<b>302,629</b>
<b>Total assets</b>	<b>1,308,858</b>	<b>1,389,348</b>	<b>1,461,955</b>
<b>Current liabilities</b>			
Total accounts payable	20,737	22,069	17,785
Total other payables	29,603	42,658	24,287
Other payables to related parties	0	6	0
Total other current liabilities	6,544	5,728	20,902
<b>Total current liabilities</b>	<b>56,884</b>	<b>70,461</b>	<b>62,974</b>
<b>Non-current liabilities</b>			
Total deferred tax liabilities	0	473	360
Total other non-current liabilities	2,256	2,271	1,729
<b>Total non-current liabilities</b>	<b>2,256</b>	<b>2,744</b>	<b>2,089</b>
<b>Total liabilities</b>	<b>59,140</b>	<b>73,205</b>	<b>65,063</b>
<b>Share capital</b>			
Ordinary share	1,120,445	1,120,005	1,117,150
Advance receipts for share capital	814	807	1,983
<b>Total share capital</b>	<b>1,121,259</b>	<b>1,120,812</b>	<b>1,119,133</b>
<b>Capital surplus</b>			
Total capital surplus, additional paid-in capital	621,871	621,104	616,540
Capital surplus, treasury share transactions	2,812	2,812	2,812
Capital surplus, employee share options	20,813	15,695	3,613
<b>Total capital surplus</b>	<b>645,496</b>	<b>639,611</b>	<b>622,965</b>
<b>Retained earnings</b>			
Total unappropriated retained earnings (accumulated deficit)	-429,426	-356,669	-257,595
<b>Total retained earnings</b>	<b>-429,426</b>	<b>-356,669</b>	<b>-257,595</b>
<b>Other equity interest</b>			
Total other equity, others	0	0	0
<b>Total other equity interest</b>	<b>0</b>	<b>0</b>	<b>0</b>
Treasury shares	-87,611	-87,611	-87,611
<b>Total equity</b>	<b>1,249,718</b>	<b>1,316,143</b>	<b>1,396,892</b>
<b>Total liabilities and equity</b>	<b>1,308,858</b>	<b>1,389,348</b>	<b>1,461,955</b>
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	44,000	44,000	103,000
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/01/01To2017/03/31	2016/01/01To2016/03/31
<b>Income Statement</b>		
Total operating revenue	25,234	9,969
Total operating costs	40,633	30,657
Gross profit (loss) from operations	-15,399	-20,688
Gross profit (loss) from operations	-15,399	-20,688
Operating expenses		
Total selling expenses	1,947	2,085
Total administrative expenses	11,023	7,078
Total research and development expenses	40,106	41,076
Total operating expenses	53,076	50,239
Net operating income (loss)	-68,475	-70,927
Non-operating income and expenses		
Total other income	6,290	13,371
Other gains and losses, net	-10,473	-2,279
Total non-operating income and expenses	-4,183	11,092
Profit (loss) from continuing operations before tax	-72,658	-59,835
Total tax expense (income)	99	65
Profit (loss) from continuing operations	-72,757	-59,900
Profit (loss)	-72,757	-59,900
Total comprehensive income	-72,757	-59,900
Basic earnings per share		
Total basic earnings per share	-0.66	-0.55

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/01/01To2017/03/31	2016/01/01To2016/03/31
<b>Statements of Cash Flows</b>		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-72,658	-59,835
Profit (loss) before tax	-72,658	-59,835
Depreciation expense	13,348	9,454
Amortization expense	234	212
Provision (reversal of provision) for bad debt expense	39	3
Interest income	-1,278	-2,452
Share-based payments	5,518	595
Loss (gain) on disposal of property, plan and equipment	-112	0
Impairment loss on non-financial assets	179	22
Total adjustments to reconcile profit (loss)	17,928	7,834
Decrease (increase) in notes receivable due from related parties	0	71
Decrease (increase) in accounts receivable	5,753	12,992
Decrease (increase) in accounts receivable due from related parties	24,183	-30
Decrease (increase) in other receivable	-2,389	-9,654
Decrease (increase) in other receivable due from related parties	0	0
Decrease (increase) in inventories	-4,470	-1,828
Decrease (increase) in prepayments	-2,196	-12,257
Decrease (increase) in other current assets	-184	-708
Total changes in operating assets	20,697	-11,414
Increase (decrease) in notes payable	0	0
Increase (decrease) in accounts payable	-1,332	-1,834
Increase (decrease) in accounts payable to related parties	0	-40
Increase (decrease) in other payable	-11,554	-10,917
Increase (decrease) in other payable to related parties	-6	0
Increase (decrease) in other current liabilities	816	9,284
Increase (decrease) in net defined benefit liability	-15	-8
Total changes in operating liabilities	-12,091	-3,515
Total changes in operating assets and liabilities	8,606	-14,929
Total adjustments	26,534	-7,095
Cash inflow (outflow) generated from operations	-46,124	-66,930
Income taxes refund (paid)	-66	-174
Net cash flows from (used in) operating activities	-46,190	-67,104
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-32,639	-72,668
Proceeds from disposal of investments in debt instrument without active market	69,167	321,709
Increase in prepayments for investments	-67,000	0
Acquisition of property, plant and equipment	-10,926	-21,243
Increase in refundable deposits	0	-171
Acquisition of intangible assets	0	0
Increase in prepayments for business facilities	-13,964	-12,737
Interest received	1,306	2,618
Net cash flows from (used in) investing activities	-54,056	217,508
Cash flows from (used in) financing activities		
Exercise of employee share options	814	1,983
Net cash flows from (used in) financing activities	814	1,983
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	-99,432	152,387
Cash and cash equivalents at beginning of period	309,771	305,619
Cash and cash equivalents at end of period	210,339	458,006
Cash and cash equivalents reported in the statement of financial position	210,339	458,006
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

**2017/03/31 Statement of Stockholders' Equity**

Unit: NIS thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Appropriated retained earnings (accumulated deficit)	Total retained earnings	Change differences on translation of foreign financial statements	Gain (losses) from investments in equity instruments measured at fair value through other comprehensive income	Realized gains (losses) on available-for-sale financial assets	Gain (losses) on effective portion of cash flow hedges	Gain (losses) on effective portion of hedges of net investments in foreign operations	Change in fair value of financial liability attributable to change in credit risk of liability	Gain (losses) on remeasurements of defined benefit	Revaluation surplus	Equity related to non-current assets classified as held for sale	Other	Total other equity items	Treasury share	Total equity	
Equity at end of period	1,120,000	807	1,120,812	639,611	-356,469	-356,469	0	0	0	0	0	0	0	0	0	0	0	0	87,611	1,316,143
Equity at beginning of period after adjustments	1,120,000	807	1,120,812	639,611	-356,469	-356,469	0	0	0	0	0	0	0	0	0	0	0	0	87,611	1,316,143
Profit (loss)	0	0	0	0	-72,757	-72,757	0	0	0	0	0	0	0	0	0	0	0	0	0	-72,757
Other comprehensive income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total comprehensive income	0	0	0	0	-72,757	-72,757	0	0	0	0	0	0	0	0	0	0	0	0	0	-72,757
Share-based payments	443	0	443	5,893	0	5,893	0	0	0	0	0	0	0	0	0	0	0	0	0	6,332
Total increase (decrease) in equity	443	0	443	5,893	-72,757	-72,757	0	0	0	0	0	0	0	0	0	0	0	0	0	-66,325
Equity at end of period	1,120,443	814	1,121,259	645,499	-429,226	-429,226	0	0	0	0	0	0	0	0	0	0	0	0	87,611	1,248,719

**2016/03/31 Statement of Stockholders' Equity**

Unit: NIS thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Appropriated retained earnings (accumulated deficit)	Total retained earnings	Change differences on translation of foreign financial statements	Gain (losses) from investments in equity instruments measured at fair value through other comprehensive income	Realized gains (losses) on available-for-sale financial assets	Gain (losses) on effective portion of cash flow hedges	Gain (losses) on effective portion of hedges of net investments in foreign operations	Equity related to non-current assets classified as held for sale	Other	Total other equity items	Treasury share	Total equity				
Equity at end of period	1,115,990	2,211	1,118,201	621,319	-197,896	-197,896	0	0	0	0	0	0	0	0	0	0	87,611	1,454,214		
Equity at beginning of period after adjustments	1,115,990	2,211	1,118,201	621,319	-197,896	-197,896	0	0	0	0	0	0	0	0	0	0	0	87,611	1,454,214	
Profit (loss)	0	0	0	0	-93,900	-93,900	0	0	0	0	0	0	0	0	0	0	0	0	-93,900	
Other comprehensive income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total comprehensive income	0	0	0	0	-93,900	-93,900	0	0	0	0	0	0	0	0	0	0	0	0	0	-93,900
Share-based payments	1,160	0	1,160	932	1,649	2,541	0	0	0	0	0	0	0	0	0	0	0	0	0	2,571
Total increase (decrease) in equity	1,160	0	1,160	932	1,649	2,541	0	0	0	0	0	0	0	0	0	0	0	0	0	2,571
Equity at end of period	1,117,150	2,211	1,119,361	622,251	-195,247	-195,247	0	0	0	0	0	0	0	0	0	0	0	0	87,611	1,396,662